Free Trial

Instil Bio Q4 2023 Earnings Report

Instil Bio logo
$21.69 -0.81 (-3.60%)
(As of 12/17/2024 ET)

Instil Bio EPS Results

Actual EPS
-$1.99
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Instil Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Instil Bio Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

DeFi Coin on Verge of Breakout! (Ad)

[FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off!

Click here to request your free copy NOW!

Instil Bio Earnings Headlines

Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Instil Bio price target lowered to $110 from $120 at H.C. Wainwright
See More Instil Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Instil Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Instil Bio and other key companies, straight to your email.

About Instil Bio

Instil Bio (NASDAQ:TIL), a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

View Instil Bio Profile

More Earnings Resources from MarketBeat

Upcoming Earnings